News | January 12, 2026
Novartis to open Florida radioligand facility
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Subscribe To Our Newsletter & Stay Updated
